CD8 T cells are activated through a sequence of three distinct signals delivered by specialized immune cells called dendritic cells. The first signal comes from recognizing a fragment of a pathogen, the second confirms the threat is real, and the third drives the massive expansion needed to fight infection. Without all three signals working together, CD8 T cells either fail to respond or become permanently unresponsive. The entire process unfolds over days to weeks, transforming a handful of pathogen-specific cells into an army of millions.
How Dendritic Cells Prepare the Antigen
Before a CD8 T cell can be activated, something has to show it what to look for. That job falls to dendritic cells, the immune system’s most effective antigen-presenting cells. Dendritic cells patrol tissues, pick up proteins from pathogens or infected cells, and break those proteins into small fragments called peptides. These peptides get loaded onto surface molecules known as MHC class I, which display them like a flag on the cell’s outer membrane.
Normally, MHC class I molecules display fragments of a cell’s own internal proteins. This is how infected cells get flagged: viral proteins made inside the cell end up on MHC class I, marking the cell for destruction. But dendritic cells have a special trick called cross-presentation, which allows them to take proteins from outside the cell and route them onto MHC class I anyway. They do this through two main pathways. In one, the swallowed protein gets shuttled from an internal compartment into the main body of the cell, where it’s chopped up by the proteasome (the cell’s protein recycling machine) and then loaded onto MHC class I. In the other, the protein is processed and loaded entirely within the compartment where it was first captured. Cross-presentation is critical because it means dendritic cells don’t need to be infected themselves to alert CD8 T cells about a pathogen.
Signal 1: Recognizing the Target
The first activation signal happens when a CD8 T cell’s receptor (the TCR) locks onto a peptide displayed on MHC class I on a dendritic cell’s surface. Each CD8 T cell has a unique receptor that fits only specific peptide shapes, so out of billions of circulating T cells, only a tiny fraction will recognize any given pathogen fragment.
This binding isn’t a solo act. A co-receptor molecule called CD8 (which gives these cells their name) plays a critical role in stabilizing the interaction. In some cases, CD8 is not just helpful but absolutely required for meaningful binding. The interaction between the TCR and the peptide-MHC complex is dynamic, involving repeated binding and release events, and CD8 helps keep the connection going long enough to trigger a response. Remarkably, T cells can detect and respond to fewer than five peptide-MHC complexes on a single dendritic cell, and this threshold appears to be consistent across different effector responses like cytokine release and killing.
Signal 2: The Costimulatory Checkpoint
Recognizing an antigen alone is not enough. Without a second confirmation signal, the T cell assumes something has gone wrong and shuts itself down permanently, a state called anergy. This safety mechanism prevents the immune system from attacking the body’s own tissues based on a single, potentially misleading signal.
The second signal comes from a receptor called CD28 on the T cell binding to molecules called B7-1 and B7-2 on the dendritic cell. Dendritic cells only display high levels of B7 molecules when they’ve detected danger signals from infection or tissue damage. This is what makes costimulation a checkpoint: it ensures the T cell only fully activates when a genuine threat is present. The combination of signal 1 (antigen recognition) and signal 2 (costimulation) together triggers the T cell to start producing growth-promoting molecules, preparing it for rapid expansion.
Signal 3: Cytokines That Drive Expansion
The third signal comes from inflammatory cytokines, small signaling proteins released during active infection. Two of the most important are IL-12 and type I interferons. These cytokines don’t give the T cell a direct growth advantage or survival benefit right away. Instead, they work by keeping the T cell sensitive to IL-2, the primary growth signal for T cells.
Here’s how it works: after activation, T cells briefly express high levels of the high-affinity IL-2 receptor on their surface. Without signal 3 cytokines, that receptor disappears quickly, and the T cell stops dividing after just a few rounds. IL-12 and type I interferons sustain the expression of that receptor, allowing the T cell to keep responding to IL-2 in its environment for a longer period. This extended sensitivity activates a pathway that drives cell cycle progression, resulting in many more rounds of division. The difference is dramatic. Without signal 3, you get a modest response. With it, a single activated CD8 T cell can generate thousands of identical effector copies.
The Role of CD4 Helper T Cells
CD8 T cells often can’t be fully activated without help from CD4 T cells, especially during responses to viruses and in situations where the initial danger signals are weak. CD4 T cells don’t help CD8 cells directly. Instead, they “license” the dendritic cell, upgrading its ability to prime CD8 T cells.
This licensing works primarily through a molecule called CD40L on the CD4 T cell binding to CD40 on the dendritic cell. When a CD4 T cell recognizes its own antigen on the same dendritic cell, this CD40 interaction boosts the dendritic cell’s expression of costimulatory molecules and cytokines, making it a far more potent activator. In experiments with human immune cells, researchers found that antigen-specific killer T cells could only be generated from naive CD8 cells when CD4 T cells were present during priming. Replacing the CD4 cells with an antibody that mimics CD40 stimulation could partially substitute, confirming that the CD40 pathway is central to this licensing effect.
Timeline From Activation to Peak Response
The activation process follows a predictable timeline, though exact numbers vary by pathogen. Data from early HIV infection provides a detailed window into how quickly things move. CD8 T cell activation becomes detectable within one to three days of initial viral replication in the blood, even before the virus reaches its highest levels. At this early stage, fewer than 1% of CD8 T cells show activation markers.
Over the following days, activated cells begin dividing rapidly. Peak proliferation occurs roughly one week after peak viral levels. The overall CD8 T cell response reaches its maximum about three weeks after the virus is first detectable, with activation markers appearing on as many as 77% of all CD8 T cells in some individuals. After that peak, the response contracts as the infection is controlled, settling to a steady state around 80 days after initial infection. During contraction, most effector cells die off, but a small fraction survives as memory cells.
What Activated CD8 T Cells Do
Once fully activated and expanded, CD8 T cells become cytotoxic, meaning they can directly kill infected cells. They use two main killing mechanisms. The dominant one is granule exocytosis: the T cell releases tiny packets containing perforin (a protein that punches holes in the target cell’s membrane) and granzymes (enzymes that enter through those holes and trigger the target cell to self-destruct). This pathway is the primary means of clearing viral infections.
The second mechanism involves a surface molecule called Fas ligand. When it binds to the Fas receptor on a target cell, it triggers a death signal inside that cell. This pathway contributes to tissue damage during infection but appears less important for actually eliminating the virus. Beyond direct killing, activated CD8 T cells also release cytokines like interferon-gamma and TNF-alpha, which can inhibit viral replication in nearby cells without killing them.
How the Immune System Applies the Brakes
Activation doesn’t go unchecked. Two key inhibitory receptors, CTLA-4 and PD-1, act as molecular brakes at different stages. CTLA-4 operates early, primarily in the lymph nodes where T cells first encounter antigen. It competes with CD28 for binding to B7 molecules on dendritic cells. CTLA-4 binds B7 with much higher affinity than CD28 but delivers no stimulatory signal, effectively blocking costimulation. This keeps the initial activation threshold high, preventing weak or self-directed responses from getting started.
PD-1 operates later, in the tissues where activated T cells carry out their work. When PD-1 binds its ligands (PD-L1 and PD-L2, which are widely expressed on normal and tumor cells), it dampens the T cell’s activity. This is a normal mechanism for winding down an immune response after the threat is cleared, but it can be exploited by tumors and chronic infections to exhaust CD8 T cells and escape immune surveillance. Cancer immunotherapy drugs that block PD-1 or CTLA-4 work by releasing these brakes, allowing exhausted or suppressed CD8 T cells to resume killing.
Effector Versus Memory Cell Fate
Not all activated CD8 T cells follow the same path. Two transcription factors, T-bet and Eomes, act as internal switches that determine whether an activated cell becomes a short-lived effector or a long-lived memory cell. T-bet drives cells toward an immediate effector fate: high killing capacity, aggressive cytokine production, but a short lifespan. Eomes promotes the development of memory cells that persist for years and can rapidly reactivate during a second encounter with the same pathogen. The balance between these two factors, influenced by the strength and duration of the signals received during activation, shapes how protective and how durable the resulting immune response will be.